Pages that link to "Q36539394"

The following pages link to Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses (Q36539394):

Displaying 40 items.

• Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity (Q27010165) (← links)
• Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design (Q27021304) (← links)
• Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus (Q28067143) (← links)
• Neutralizing antibody response and SARS severity (Q28385241) (← links)
• Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. (Q30425776) (← links)
• Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. (Q30485791) (← links)
• Primary Human mDC1, mDC2, and pDC Dendritic Cells Are Differentially Infected and Activated by Respiratory Syncytial Virus (Q33813095) (← links)
• Mucosal vaccines against respiratory syncytial virus (Q33837530) (← links)
• Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro (Q33964142) (← links)
• Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1 (Q34175747) (← links)
• Current concepts and progress in RSV vaccine development. (Q34396689) (← links)
• Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles (Q34661842) (← links)
• Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract (Q35690781) (← links)
• Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains (Q36363325) (← links)
• Neonatal calf infection with respiratory syncytial virus: drawing parallels to the disease in human infants (Q36482799) (← links)
• Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection (Q36483809) (← links)
• Respiratory syncytial virus and innate immunity: a complex interplay of exploitation and subversion (Q36530226) (← links)
• Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma (Q36810987) (← links)
• Tiotropium Attenuates Virus-Induced Pulmonary Inflammation in Cigarette Smoke-Exposed Mice (Q36947774) (← links)
• Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. (Q37071608) (← links)
• Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus. (Q37412509) (← links)
• Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut (Q37615056) (← links)
• The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development. (Q38068469) (← links)
• Respiratory syncytial virus--a comprehensive review (Q38098094) (← links)
• Central nervous system alterations caused by infection with the human respiratory syncytial virus. (Q38260281) (← links)
• Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality? (Q38868960) (← links)
• Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection (Q39027049) (← links)
• Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands (Q39436774) (← links)
• The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis (Q40021220) (← links)
• Inhibition of Respiratory Syncytial Virus Replication by Simultaneous Targeting of mRNA and Genomic RNA Using Dual-Targeting siRNAs. (Q40476115) (← links)
• A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus (Q40512544) (← links)
• Antigen-dependent proliferation and cytokine induction in respiratory syncytial virus-infected cotton rats reflect the presence of effector-memory T cells (Q45460509) (← links)
• Formalin-inactivated bovine RSV vaccine influences antibody levels in bronchoalveolar lavage fluid and disease outcome in experimentally infected calves (Q46310621) (← links)
• Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge. (Q51983228) (← links)
• Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus. (Q52649839) (← links)
• Systematic comparison of respiratory syncytial virus-induced memory B cell responses in two anatomical compartments (Q64117055) (← links)
• Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity (Q64118246) (← links)
• Impact of Respiratory Syncytial Virus Infection on the Host Cell: Implications for Antiviral Strategies (Q90681995) (← links)
• Staphylococcus aureus-specific IgA antibody in milk suppresses the multiplication of S. aureus in infected bovine udder (Q92531294) (← links)
• Respiratory Syncytial Virus Infection Reduces Kynurenic Acid Production and Reverses Th17/Treg Balance by Modulating Indoleamine 2,3-Dioxygenase (IDO) Molecules in Plasmacytoid Dendritic Cells (Q103825959) (← links)